RTW Investments’s Janux Therapeutics JANX Stock Holding History

RTW Investments’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,000,000	Closed	-$37.6M	–	71
2024 Q1	$37.6M	Buy	+1,000,000	New	+$21.8M	0.56%	44

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments's JANX Position: Q2 2024 in Review

RTW Investments sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 1,000,000 shares — an estimated $37.6M sold.

RTW Investments first reported a position in JANX in Q1 2024 and held it in 1 quarter. The position peaked at $37.6M in Q1 2024. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

RTW Investments reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
RTW Investments sold 1,000,000 Janux Therapeutics shares in Q2 2024, an estimated $37.6M.
RTW Investments first reported a position in Janux Therapeutics in Q1 2024 and held it in 1 quarter.
RTW Investments's Janux Therapeutics position peaked at $37.6M in Q1 2024.
155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on RTW Investments's 13F filing for Q2 2024, filed 14 Aug 2024.